0000950170-24-016695.txt : 20240216 0000950170-24-016695.hdr.sgml : 20240216 20240216213118 ACCESSION NUMBER: 0000950170-24-016695 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240214 FILED AS OF DATE: 20240216 DATE AS OF CHANGE: 20240216 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Henn Matthew R. CENTRAL INDEX KEY: 0001767321 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37465 FILM NUMBER: 24650402 MAIL ADDRESS: STREET 1: C/O SERES THERAPEUTICS, INC. STREET 2: 200 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Seres Therapeutics, Inc. CENTRAL INDEX KEY: 0001609809 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 274326290 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617 945 9626 MAIL ADDRESS: STREET 1: 200 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Seres Health, Inc. DATE OF NAME CHANGE: 20140603 4 1 ownership.xml 4 X0508 4 2024-02-14 0001609809 Seres Therapeutics, Inc. MCRB 0001767321 Henn Matthew R. C/O SERES THERAPEUTICS, INC. 101 CAMBRIDGE PARK DRIVE CAMBRIDGE MA 02140 false true false false See Remarks true Common Stock 2024-02-15 4 M false 11250 A 67606 D Common Stock 2024-02-16 4 S false 4170 1.08 D 63436 D Stock Option (Right to Buy) 1.10 2024-02-14 4 A false 187500 0.00 A 2034-02-13 Common Stock 187500 187500 D Stock Option (Right to Buy) 1.10 2024-02-14 4 A false 287905 0.00 A 2034-02-13 Common Stock 287905 287905 D Restricted Stock Units 2024-02-14 4 A false 31250 0.00 A Common Stock 31250 31250 D Restricted Stock Units 2024-02-15 4 M false 11250 0.00 D Common Stock 11250 33750 D Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on April 13, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. The price reported in column 4 is a weighted average of the price. These shares were sold in multiple transactions at prices ranging from $1.08 to $1.115, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The option will vest as to 25% of the shares on February 14, 2025. The remainder of the shares will vest in 12 equal quarterly installments thereafter. The option will vest, if at all, in two substantially equal installments upon achievement of a 30-day trailing average public market closing price per share of the Issuer's common stock greater than or equal to $3.00 and $5.00, respectively. The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. Chief Scientific Officer and EVP /s/ Thomas J. DesRosier, attorney-in-fact for Matthew R. Henn 2024-02-16